JNJ-77242113 for Ulcerative Colitis
(ANTHEM-UC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new medication called JNJ-77242113 to see if it can help people with moderately to severely active ulcerative colitis. The medication aims to reduce inflammation in the colon by calming the immune system. Researchers want to find out if it is safe and effective.
Do I need to stop my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. Please consult with the trial coordinators for more details.
What safety data exists for JNJ-77242113 in humans?
The safety of Janus kinase (JAK) inhibitors, like JNJ-77242113, has been studied in other similar drugs such as tofacitinib and peficitinib, which are used for ulcerative colitis. These studies show that while JAK inhibitors can be effective, they may also have some toxicities, so their safety profile is carefully evaluated in clinical trials.12345
How is the drug JNJ-77242113 different from other treatments for ulcerative colitis?
JNJ-77242113 is likely a Janus kinase (JAK) inhibitor, similar to tofacitinib and peficitinib, which are used for ulcerative colitis. These drugs work by blocking specific enzymes involved in the inflammation process, offering a different approach compared to traditional treatments like corticosteroids or anti-TNFα therapies.13467
What data supports the effectiveness of the drug JNJ-77242113 for treating ulcerative colitis?
Who Is on the Research Team?
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Are You a Good Fit for This Trial?
This trial is for adults with ulcerative colitis that's been active for at least 12 weeks and hasn't improved with standard treatments. It's not suitable for those whose condition is limited to the rectum or a short section of the colon, have had significant colon surgery, or have other types of bowel diseases.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive JNJ-77242113 or placebo tablets orally from Week 0 through Week 28
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term Extension
Participants who achieve clinical response at Week 28 may continue treatment up to Week 76
What Are the Treatments Tested in This Trial?
Interventions
- JNJ-77242113
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Joaquin Duato
Janssen Research & Development, LLC
Chief Executive Officer since 2022
MBA from ESADE, Master of International Management from Thunderbird School of Global Management
Dr. Jijo James, MD
Janssen Research & Development, LLC
Chief Medical Officer since 2014
MD from St. Johns Medical College, MPH from Columbia University